Click on a filter below to refine your search. Remove a filter to broaden your search.
However, the introduction of new insulin products after 2015 was followed by substantial discounting practices that lowered net prices.
The findings were seen among low-income individuals with diabetes and poor glycemic control.
The findings were seen even after controlling for sociodemographic and other health factors.
A strong recommendation was given for the addition of an SGLT-2 or GLP-1 agonist to metformin, and lifestyle modifications.
The bill now has to pass the Senate with at least 10 Republican votes.
Despite a drop in diabetes-related outpatient visits and testing, no negative association was found with glycemic control.
The company will cut its list price for Humalog 100 units/mL starting in the fourth quarter of 2023.
But the biggest policy change — letting Medicare negotiate prices for prescription drugs — will not start to lower costs until 2025.
Among adults with three or more chronic conditions, Medicare was the most frequently observed expected source of payment.
Under the law, Medicare will now be allowed to negotiate the cost of some drugs, and vaccines will be free for Part D recipients.